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ABSTRACT 
Major depressive disorder in adolescents is an important public health concern. It is common, a risk 
factor for suicide and is associated with adverse psychosocial consequences. The UK NICE guidelines 
recommend that children and young people with moderate to severe depression should be seen 
within Child and Adolescent Mental Health Services and receive specific psychological interventions, 
possibly in combination with antidepressant medication.  Cognitive-behavioural therapy (in some 
studies) and interpersonal psychotherapy have been demonstrated to be more effective than active 
control treatments for depressed adolescents. For children with depression, there is some evidence 
that family focused approaches are more effective than individual therapy. Fluoxetine is the 
antidepressant with the greatest evidence for effectiveness compared with placebo. Treatment with 
antidepressants and/or psychological therapy is likely to reduce suicidality, although in some young 
people, SSRIs lead to increased suicidality. There is limited evidence that combination of specific 
psychological therapy and antidepressant medication is better than treatment with monotherapy. 
There are methodological limitations in the published literature that make it difficult to relate study 
findings to the more severely ill clinical population in Child and Adolescent Mental Health Services. 
Young people should have access to both evidence based psychological interventions and 
antidepressants for paediatric depression.  Collaborative decisions on treatment should be made 
jointly by young people, their carers and clinicians, taking into account individual circumstances and 
potential benefits, risks and availability of treatment.   
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INTRODUCTION 
Major depressive disorder is common in adolescence; lifetime prevalence rates vary from 11-20%(1–
3). Major depressive disorder is an important risk factor for suicide(4), a leading cause of death in 
young people(5–7) and co-morbidity with other psychiatric disorders is common(8). 
This paper will give an overview of recent developments in the treatment of depression in children 
and adolescents. Almost all studies only included adolescents, and it will be specifically stated if a 
study included children.  
WHAT DO DEPRESSIVE DISORDERS LOOK LIKE IN CHILDREN AND ADOLESCENTS? 
Feeling sad or irritable is a normal reaction to stress. However, depression is an illness and is more 
than feeling sad: low mood becomes enduring (two weeks or more), and is commonly accompanied 
by other symptoms, such as sleep difficulties, not wanting to eat, negative thoughts and feeling 
tired. It commonly interferes with everyday life and is associated with functional impairment at 
home, school and in relationships. The core features of depression are similar in children, 
adolescents and adults (see table 1). 
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Table 1: Criteria for ICD-10 depressive episode(9)   
Depression Severity  
 
For an episode of depression symptoms need to 
be present for a duration of at least 2 weeks in 
all three grades of severity.  
 
Mild: 
2 key symptoms 
2 associated symptoms 
 
Moderate: 
2 key symptoms 
3-4 associated symptoms 
 
Severe: 
3 key symptoms 
4 associated symptoms 
 
 
Key symptoms:  
 Depressed mood  
 Loss of interest and enjoyment in 
activities 
 Decreased energy and fatigability  
Associated symptoms:  
• Reduced ability to concentrate 
• Loss of self-esteem or self confidence 
• Excessive thoughts of guilt or 
worthlessness 
• Despairing and pessimistic view of the 
future 
• Thoughts or acts of self-harm or suicide 
• Disrupted sleep   
• Loss of appetite  
 
What treatments are effective for depressive disorders in children and adolescents? 
It has been shown that contact with mental health services is beneficial for adolescents with 
depressive symptoms(10). It is important that services offer treatments with the best evidence base.   
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Psychological interventions  
The NICE guidelines(11) for the treatment of mild depression recommend a period of 4 weeks 
watchful waiting and after this period non-directive supportive therapy, group cognitive behavioral 
therapy (CBT) or guided self-help. If there has been no response for 2-3 months using these 
treatment modalities, then a referral should be made to specialist Child and Mental Health (CAMH). 
Young people with moderate to severe depression should be offered a specific psychological therapy 
as a first-line treatment: individual CBT, interpersonal psychotherapy (IPT) or family therapy (FT). 
The NICE guidelines suggest that such a therapy should be given for at least 3 months duration. A 
recent meta-analysis of psychological therapies for depression in children/adolescents found a 
standardized effect size of 0.29(12). Given the higher cost and lower availability of the specialist 
therapies recommended by NICE in comparison to non-specific treatment as usual (TAU) or 
counselling, it is important that they are shown to have significantly different efficacy.   
Cognitive Behavioural Therapy  
CBT is the treatment most studied for adolescent depression.  It aims to increase helpful behaviours 
(such as going out more) and modify negative thinking.  Earlier studies suggested a very high effect 
size, but more recent studies (with more active control treatment and more robust methodology) 
demonstrate more modest effect sizes.  A meta-analysis of CBT studies versus controls reported a 
standardized mean difference (SMD) in favour of CBT of 0.53 (p<0.01). However, the methodology of 
many of these studies was poor, and limiting inclusion to studies with better methodology revealed 
much smaller effects (eg SMD for studies using intention to treat analysis was 0.26, p <0.05; SMD for 
studies with active control groups was 0.11, p<0.01)(13). The CBT used in RCTs has at times been 
criticised for being too rigid and not being totally focused on each individual’s problems.  A 
modular(14) approach to CBT, with flexible application of manualised focused treatment for the 
problems a young person (including depression, anxiety and behaviour problems) has been shown to 
be more effective than treatment as usual. 
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Interpersonal Therapy (IPT) 
IPT aims to reduce depressive symptoms by improving relationships, using techniques such as 
communication analysis and building up positive social networks.  The only study of IPT for 
depression in adolescents with an active control group (TAU) found an SMD in favour of IPT of 0.50 
(p=0.04)(15). This study also showed that the IPT-TAU difference was significantly higher in those 
with moderate, as opposed to mild/sub-threshold depression.  However, this study requires 
replication. 
Family Therapy (FT) 
FT examines family relationships and tries to improve conflicts and other dysfunction, however, it 
has not been found to be more effective than control treatments for adolescent depression, 
whether as a single therapy or combined treatment(16–18).  A more recent trial compared FT to 
individual psychodynamic psychotherapy (PPT) and found no significant difference(19). However, 
this study did not have a TAU control group. Psychodynamic Psychotherapy (PPT) has not been 
demonstrated to be more effective than a brief psychosocial intervention (BPI)(20). A pilot study of 
Attachment-Based Family Therapy (ABFT) suggested it may be effective for depression, but a fully 
powered study showed no significant difference in depressive symptoms between ABFT and 
TAU(21). Taking these studies together, family therapy does not appear to be any more effective 
than TAU for depression in adolescents. 
Only one small (n=42) Randomised Controlled Trial (RCT) of psychological therapy for depression has 
targeted children (age 7-12), rather than adolescents.  IPT was adapted so there was much greater 
parental involvement - family-based interpersonal therapy (FB-IPT).  FB-IPT was more effective than 
more individually-based client-centred therapy for 38 7-12-year olds with a depressive disorder 
(remission rates 66% vs 31%, p = 0.04)(22) (Dietz 2015).  A recent moderate-sized (n=154) study 
showed FT to be more effective than individual therapy for 7-14-year olds with depression(23). Thus, 
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a family-based approach may be more effective than individual therapy in children/younger 
adolescents. 
Psychodynamic psychotherapy (PPT) 
PPT focuses on interpersonal relationships, attachment and life stresses, and explicitly works on the 
therapeutic relationship between the client and therapist. A recent large UK based RCT (IMPACT, 
n=465) compared PPT, CBT and a manualized brief psychosocial intervention (BPI)(20). There was no 
difference between treatments over 86 weeks follow-up. This suggests that both PPT and BPI are as 
effective as CBT, up to now the most-widely supported and used treatment for adolescent 
depression.  
Network Meta-Analysis Comparing Psychological Therapies 
Network meta-analysis (NMA) allows two-way comparisons to be inferred from the results of other 
studies comparing treatments (24).  A recent NMA of psychological therapies for child and 
adolescent depression found IPT and CBT both to be significantly more effective than treatment as 
usual, placebo and waiting-list(25).  IPT and CBT were not significantly different from each other at 
post-intervention or short-term follow-up; IPT was significantly better than CBT at long-term follow-
up.  FT, problem-solving therapy and supportive therapy were significantly better than waiting-list 
but did not differ from placebo or TAU.  Play therapy did not differ from waiting-list.  PPT did not 
significantly differ from other interventions, although this NMA did not include the later IMPACT 
study. Of note, this NMA did include older studies with less-robust methodology (such as not using 
intention-to-treat) and merged all studies using the same treatment model, although they could vary 
in terms of delivery (eg group/individual, internet/face-face).  
Pharmacological interventions 
NICE do not recommend antidepressant medication for the initial treatment of mild depression in 
the paediatric population. The updated guidelines indicate that fluoxetine can be considered in 
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combination with specific psychological therapy for young people (age 12-18) in the initial treatment 
of moderate to severe depression. In children (aged 5-11) the combination of fluoxetine with 
psychological treatment should be considered with caution and only after 4-6 sessions of 
psychological therapy. The starting dose of fluoxetine is 10mg once daily increasing to a standard 
dose of Fluoxetine 20mg once daily for 4-6 weeks with review at each stage of the treatment 
pathway(11). The British National Formulary (BNF) suggests that fluoxetine can be given to a 
maximum dose of 60mg; there is no evidence to indicate that using such a high dose is effective or 
not effective in adolescents; dosage should be governed by individual response, tolerance of any 
adverse effects, and should be kept to the lowest possible dose required to achieve an adequate 
response. These guidelines suggest sertraline or citalopram as second line treatment.  They 
recommend that venlafaxine, paroxetine and tricyclic antidepressants should not be used due to 
significant side-effects. The most recent Cochrane review on tricyclic antidepressants for paediatric 
depression(26) found no benefit on remission or response rates, when compared with placebo. 
There was a small reduction in depression scores amongst adolescents treated with tricyclics 
compared with placebo. Adverse effects were more notable in the tricyclic, versus placebo, group.  
The most recent Cochrane meta-analysis on newer generation antidepressants(27) demonstrated 
that the drug-placebo difference is greatest for fluoxetine, with an absolute mean difference 
between treatments of 5.63 on the CDRS-R and a risk ratio for response of 1.47. The largest (and 
non-drug company funded) RCT of fluoxetine (Treatment for Adolescents with Depression Study) 
had a response rate of 61% in the fluoxetine group and 35% in the placebo group at 12 weeks. The 
Cochrane review also demonstrated that escitalopram and sertraline were significantly superior to 
placebo.  However, other SSRIs, venlafaxine and mirtazapine were not significantly better than 
placebo. 
A recent network meta-analysis (NMA) compared antidepressants, based on indirect comparisons 
across studies, again found the drug-placebo difference to be greatest for fluoxetine (SMD 0.51)(28). 
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The study did not find a significant difference between fluoxetine and other NGAs, although these 
findings are constrained by methodological issues(29).  Head-head comparisons also found 
escitalopram and sertraline to be superior to placebo, although this did not remain significant in the 
more conservative random-effects analysis used in the NMA.   
There were justified concerns about risk of bias from the authors, due to limited information, high 
dropout rates and no details on allocation concealment across studies.  The population used in the 
trials were unlikely to be representative of clinic populations, as those with co-morbid psychiatric 
disorders and high suicide risk were generally excluded from individual studies. 
Evidence and guidance on how long to continue antidepressants for is not clear.  Guidelines for adult 
depression suggest that they should be continued for six-nine months after remission in first episode 
cases with lower risk of relapse, and a longer duration in higher risk/recurrent cases(30). 
Potential Harms from Antidepressants 
The most recent Cochrane review on NGAs reported that adverse effects were greater in those 
taking antidepressants (11 trials N=2136 RR 1.11, 95% CI 1.05 to 1.17). The most commonly noted 
physical side-effects were headaches, abdominal pain, dizziness and nausea. Emotional lability was 
more often associated with paroxetine, fluoxetine and sertraline. In addition, mirtazapine was 
reported to increase metabolic side effects (increased appetite, weight gain and 
hyperlipidaemia)(26). TADS found that emotional and behavioral disinhibition and non-psychiatric 
adverse events were greater in the Fluoxetine treated groups(31). The risk of conversion to 
mania/manic symptoms with SSRIs is higher for depressed adolescents than adults, although there is 
no clear evidence that the conversion to full mania/hypomania is more common with SSRIs than 
placebo in depressed adolescents (32).    
In 2003, The USA Food and Drugs Administration (FDA), followed soon by the Medicines & 
Healthcare Products Regulatory Agency United Kingdom (MHRA UK), released warnings about 
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increased risk of suicidality from SSRIs in paediatric patients. They advised that clinicians balance the 
risk of suicidality with clinical need in antidepressant treatment for pediatric patients. They 
recommend that fluoxetine be the first-line drug treatment for pediatric major depressive disorder.  
The meta-analysis by the FDA on suicide related adverse events included 4582 patients from 24 
pediatric trials. Data for SSRIs (fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram) showed a 
modest increased risk of suicidality in 20 trials (RR 1.66 95% CI 1.02-2.68)(33). 
However, although it has been shown that suicidality does increase in some individual young people 
taking SSRIs, on average it reduces across samples of young people, when measured 
prospectively(31).  Of note, Gibbons and colleagues carried out a recent and more robust meta-
analysis using individual-level data (as opposed to aggregate results from studies) from published 
and unpublished studies on adolescent depression. Suicidality reduced in both fluoxetine and 
placebo groups, and there was no significant difference between groups. On the other hand, 
depressive symptoms improved more in the fluoxetine group.  While this study does not support the 
hypothesis that SSRIs increase suicidality more than placebo, it also suggests that reduction of 
depression is not the sole mechanism for reducing suicidality(34).  Also, non-controlled but larger 
and more representative community-based studies have suggested that higher rates of SSRI 
prescribing are associated with lower suicide rates; and that suicide attempts are more common 
before SSRI prescribing than after it(35). 
In view of this small risk of a very important adverse event, antidepressant medication initiation and 
adverse outcomes need to be monitored carefully by appropriately-trained doctors, such as child 
and adolescent psychiatrists.  The risk of increased suicidality needs to be weighed against the risk of 
inadequately-treated depression. 
It is difficult to extrapolate the results from these trials to the more severely depressed and complex 
patients seen in clinics, as studies usually excluded patients with severe depression, co-morbidity 
and/or suicidality and the drug-placebo difference may be greater in more severe depression (as 
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seen in both adolescents and adults(36,37)).  Most importantly, the effects of antidepressants on 
suicidality in people with pre-existing suicidal thoughts is unknown, as these individuals are usually 
excluded from medication trials. 
Potential Harms from psychological intervention 
Little consideration has been given to date of the potential harms of psychotherapy in the 
adolescent population which could be a result of either ineffective practice, ineffective engagement 
or specific adverse events(38). Examples of adverse effects could include dependence on the 
therapist, poor quality therapy which could also deter future acceptance of therapy; and feelings of 
failure for not ‘succeeding’ in psychological tasks.   
 
Comparisons/Combinations of Psychological and Pharmacological Interventions  
The most recent Cochrane review on psychological therapies versus antidepressant medication, 
alone and in combination, for child/adolescent depressive disorder identified 11 trials(39). However, 
given that the meta-analyses for antidepressants demonstrated differential efficacy for different 
SSRIs, it may not be appropriate to combine studies using different antidepressants.  2 studies were 
found comparing SSRIs to psychological therapy (CBT), and the pooled odds ratio for remission was 
non-significantly in favour of SSRI (0.62, CI 0.28-1.35).  However, the study that compared fluoxetine 
to CBT demonstrated that fluoxetine (response rate = 61%) was significantly better than CBT 
(response rate 43%, OR 0.49, CI 0.28-0.84)(30), while the study comparing sertraline to CBT showed 
CBT to be non-significantly better than sertraline(40). 
Outcome data from 3 trials comparing combination therapy and antidepressant medication showed 
that combination treatment was more likely to lead to remission than antidepressant medication 
alone, but this difference was not statistically significant (OR 1.50, 95% CI 0.99 to 2.27). There was 
no significant difference overall when the two studies comparing combination therapy and CBT were 
13 
 
pooled.  However, again this may have been due to clinical heterogeneity: combined treatment with 
fluoxetine and CBT was significantly better than CBT alone (TADS, OR = 2.94, 95% CI 1.67 to 5.18) 
and combined treatment was better than fluoxetine alone on some outcome measures only(31); 
whilst combined treatment with sertraline and CBT was non-significantly worse than CBT alone(40).   
One RCT looked at treatments for depressed adolescents who had not responded to treatment with 
one SSRI(41). Participants were randomized in two ways:  to another SSRI or venlafaxine; and to CBT 
or non-CBT.  The addition of CBT was more effective on some outcome measures (eg response rate, 
54.8% vs 40.5%, p = 0.009), but not others (including continuously measured depression severity, 
SMD 0.09 at 12 weeks).   
Given the evidence that NGAs increase suicidality compared to placebo, it is important to compare 
this adverse outcome between different treatments. TADS randomized 439 depressed adolescents 
to fluoxetine alone, CBT alone, combined CBT and fluoxetine or placebo. Suicidality (measured on a 
continuous scale) reduced in all treatment groups.  At 12 weeks, this reduction was significantly 
greater in the combined treatment group than either fluoxetine alone or CBT alone; there was no 
significant difference between fluoxetine alone and CBT alone. There was no significant difference in 
suicide-related events at 12 weeks(31).  However, at 36-week follow-up, suicidal events were 
significantly greater in the fluoxetine alone (15%) than the CBT alone (6%) group, which was 
statistically significant (p = 0.04)(41). There was no statistically significant difference between 
combined treatment and either monotherapy. However, the p-values have not been corrected for all 
treatment contrasts for suicidal events across the four treatment groups (fluoxetine alone, CBT 
alone, combined CBT and fluoxetine or placebo). 
In the UK, the ADAPT study compared CBT plus SSRI against SSRI alongside specialist clinical care 
over 28 weeks.  There was no evidence of a protective effect of CBT as there were no significant 
differences in suicidal thoughts or self-harm events between SSRI alone and combined 
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treatment(43).  Similarly, in the TORDIA study for adolescents with treatment-resistant depression, 
there was no evidence of a protective effect of CBT(41). 
Sleep and depression 
Sleep disturbance in adolescent depression is common, with 92% [n=427] of depressed adolescents 
in the IMPACT study reporting sleep problems(20). Loss of sleep can increase the likelihood of 
developing depressive symptomatology and risk taking behaviours(44). Sleep disturbance worsens 
the course of depression in depressed adolescents(45). The assessment and management of sleep 
problems is an important component of the treatment of adolescent depression. Specific treatments 
for insomnia may involve psychological or pharmacological interventions, although studies are 
limited for the adolescent population(46).   
Moderators of treatment response  
When the difference between treatment groups is significantly different for patients with and 
without a baseline variable, that variable acts as a moderator.  The identification of moderators 
helps us to target the appropriate treatment for individual patients.  TADS demonstrated that milder 
depressive symptoms and greater cognitive distortions each led to the difference between 
combined fluoxetine plus CBT and fluoxetine alone to be significantly greater; and also that the 
difference between CBT and placebo was significant in young people from high income families 
only(47).  In TORDIA, the addition of CBT was more likely to be effective in adolescents with more 
co-morbid disorders, and less likely to be effective in young people who had experienced child 
maltreatment(48). 
Social Interventions 
The NICE guidelines emphasise the importance of managing the context of depression: 
‘Comorbid diagnoses and developmental, social and educational problems should be assessed and 
managed, either in sequence or in parallel, with the treatment for depression. Where appropriate 
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this should be done through consultation and alliance with a wider network of education and social 
care. Attention should be paid to the possible need for parents’ own psychiatric problems 
(particularly depression) to be treated in parallel’(11).  
 
Long-Term Outcome and Relapse prevention 
Long-term follow-up of the TADS sample showed that 91.5% of adolescents met criteria for recovery 
within 2 years and 96.4% recovered within 63 months. 46.6% of those who recovered had a 
recurrence of depression.  Initial treatment group had no effect on recovery nor recurrence.  This 
lack of non-difference at follow-up was also found in a smaller earlier study, which demonstrated 
CBT to be better than FT and supportive therapy in the short-term(17); there was no difference 
between groups at 2-year follow-up(49).  As stated above, the IMPACT trial demonstrated no 
difference between CBT, PPT and BPI over 86 weeks; there was no significant difference between 
treatments at any time(20). A separate pooled analysis consisting of three studies compared 
antidepressant treatment against placebo, and reported that antidepressants were significantly 
better for relapse/recurrence prevention (OR = 0.34, 95% CI 0.18-0.64)(26). 
There is also evidence that the risk of relapse may be reduced by adding sequential CBT, as opposed 
to continuation pharmacotherapy alone, after a successful antidepressant response. Of 144 children 
and adolescents who had responded to fluoxetine treatment, only 9% relapsed with continuation  
treatment combined with CBT, versus 26.5% who were treated with fluoxetine alone after 30 
weeks(50). 
 
Preventative strategies  
The most recent Cochrane review on interventions for preventing depression in children and 
adolescents included psychological only interventions. The updated review identified 83 trials in a 
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qualitative synthesis. The population selected were children and adolescents aged 5 to 19, who had 
not yet received a primary diagnosis of depression with no restrictions on setting. The evidence-
based psychological interventions included were IPT-orientated, CBT-orientated and third-wave CBT. 
The latter is a group of psychotherapy approaches; which in this updated review included dialectical 
behavioural therapy (DBT), positive psychology, mindfulness, acceptance and commitment therapy 
(ACT) and behaviour therapy). Data from 32 trials revealed a reduction of risk of diagnosis with 
depression in the medium term (up to 12 months) for those receiving psychological evidence-based 
interventions (CBT, third-wave CBT and IPT) compared with no intervention (Risk Difference -0.03, 
95% CI -0.05 to -0.01 p=0.01). This effect was not maintained at longer term follow-up. Whilst there 
were small benefits of depression prevention, the quality of evidence was rated as low and results 
heterogenous(51).   
Online interventions 
There is an exponential growth in the development of mobile apps and computerised technologies, 
however, there is limited evidence base for the use of apps for mental health disorders in 
adolescents(52). It has been suggested that the use of Digital Health Interventions (DHIs) for mental 
health problems is accessible, efficient and effective. A systemic and meta-review on DHIs in young 
people, yielded 6 RCTs for depression, however, 5 trials excluded participants with severe 
depression. There was some support for the use of Computerised Cognitive Behavioural Therapy 
(cCBT) in young people with mild depression and anxiety. There were significant methodological 
limitations, effectiveness was found to be inconclusive, and there was lack of data on cost-
effectiveness of treatment(53).  
Implications for clinical practice 
It is not easy to draw conclusions that apply to clinic populations from the literature.  This is partly 
due to methodological limitations which apply to studies of both antidepressants and psychological 
therapies; in particular, the use of waiting-lists or inactive controls as comparators makes it 
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impossible to tell whether the therapy is specifically effective, or if improvement is a result simply of 
time spent with a caring therapist.  In addition, psychological treatment trials rarely examine adverse 
effects although there is a growing literature about potential harms. The evidence base has 
suggested that both IPT and CBT are more effective than treatment as usual, however, the IMPACT 
study reported no difference between PT, CBT and a brief manualised psychosocial intervention 
both in the short and longer term. Family based interventions are likely to be effective for younger 
children.  With regards to antidepressants, there is evidence from several studies (the largest one of 
which was not funded by a drug company) that fluoxetine is more effective than placebo, with 
weaker evidence in favour of sertraline and escitalopram.  There is limited evidence that combined 
treatment is better than monotherapy. Continuation treatment with antidepressants significantly 
reduces the risk of relapse, and sequential treatment with CBT in fluoxetine responders may be of 
additional benefit in preventing relapse. All treatments should be given within a psychosocial 
framework with a considered formulation of risk and protective factors. The major limitation of all 
these studies is that almost all excluded patients with severe depression, co-morbid disorders 
and/or suicidality.  These are precisely the complex patients seen in CAMHS that need a robust 
evidence base for treatment. 
The NICE guidelines recommend starting treatment with a specific psychological therapy in 
moderate to severe adolescent depression, however combined treatment with fluoxetine and 
psychological therapy may be considered as a first-line approach in more severe cases.  This is based 
partly on risk of side-effects with medication.  Weighing up the benefits and risks of treatment 
options for each young person is complex and made harder by the long waiting-lists for 
psychological therapies in many places.  Young people and their families should be told of the 
potential benefits and, harms, as well as waiting-lists, for treatments and be enabled to make fully 
informed, collaborative decisions about the most appropriate treatment choice for them. Future 
research needs to focus on the most impaired and suicidal young people, as well as those that do 
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not respond to first-line treatments and evaluate the potential benefits and harms of both 
antidepressants and psychological therapies. 
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